KRAS and neoplasm: Overall, immune checkpoint blockade demonstrates heterogenous activity in KRAS-mutated NSCLC on the basis of KRAS amino acid substitution, smoking exposure, tumor mutational burden, and co-mutation status (i.e., STK11 or KEAP1).29